• Daniel B Spoon, Sean Tunis, Jay Giri, James T Maddux, Ashwin Nathan, Soumya G Chikermane, Michael Reed, Joseph Schmoker, Travis Abicht, Joseph Walsh, Jeffrey Heslop, Jeff Zweifel, and David Holmes.
• Providence Montana, Missoula, MT, USA. Electronic address: Daniel.Spoon@providence.org.
• Mayo Clin. Proc. 2024 Jul 5.

ObjectiveTo compare transcatheter aortic valve replacement (TAVR) outcomes during the period when public health emergency (PHE) flexibilities were in place with outcomes during a period before they were introduced.MethodsPatients who received a native TAVR with either a SAPIEN 3 or SAPIEN 3 Ultra valve from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry between June 22, 2019, and August 30, 2022, were placed into one of two cohorts: (1) pre-PHE cohort, and (2) peri-PHE cohort. Outcomes included in-hospital events and events occurring 30 days post-TAVR. Patients were matched 1:1 on their propensity of receiving a TAVR during the pre- or peri-PHE periods. After matching, relative risk was calculated for each in-hospital outcome and HRs for outcomes 30 days post-TAVR.ResultsIn this study, 173,434 patients met inclusion criteria; after 1:1 matching, there were 37,063 patients in each cohort. There was no difference between cohorts in in-hospital outcomes, including all-cause mortality, stroke, composite of mortality and stroke, pacemaker, or major vascular complications. Similarly, there was no statistically significant difference in 30-day outcomes between the cohorts.ConclusionIn this large-scale retrospective study of 74,126 patients undergoing TAVR procedures from 2019 to 2022, no significant differences existed in TAVR outcomes during the PHE period.Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

6 keywords...

hide…